It's not often that a pathologist gets to make a diagnosis that works for the patient by preventing treatment from occurring.

The global soft tissue sarcoma market is poised for substantial growth from 2024 to 2035, driven by the rising prevalence of this rare, aggressive cancer affecting connective tissues. Key growth ...

When Gleevec was invented, or when it came out, that was a game-changer for patients with GIST, because they previously had ...

Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across multiple soft tissue sarcoma subtypes including rare and highly aggressive ...

The IDEXX Cancer Dx is a new blood-based screening/diagnostic panel aimed at detecting canine lymphoma from serum or whole ...

BOCA RATON, FL / ACCESS Newswire / December 3, 2025 / For a micro-cap biotech, the usual headlines bounce between cash raises, compliance updates, and board-room reshuffles. Once in a while, though, ...

DelveInsight's Rhabdomyosarcoma Market Insights report includes a comprehensive understanding of current treatment practices, ...

Dr. Dowdle, a microbiologist who became the No. 2 official at the Centers for Disease Control and Prevention, helped lead the ...

HER back pain was so debilitating she couldn’t sleep and had to crawl to the bathroom. Even more frighteningly, she was rapidly losing weight and her spine was making loud cracking noises that ...